seperator

Ethris’ Core Disease Areas

seperator

 

Ethris’ SNIM® RNA technology could have broad applications in treating many diseases. Our pipeline consists of immuno-modulation and mRNA-based protein replacement therapy programs for several pulmonary disease indications.

Immuno-modulation therapies

Covid-19
Covid-19 is an infectious disease caused by the novel coronavirus, SARS-CoV-2, with symptoms varying from fever, cough, fatigue and breathing difficulties to acute respiratory distress syndrome. Ethris has partnered with Neurimmune to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies that can be administered directly to the lung via inhalation. By targeting the mRNA to the lung, we can facilitate the production of specific neutralizing antibodies directly in patients’ lungs and can significantly impact the viral infection.

Influenza
Ethris aims to leverage its proprietary SNIM® RNA technology to develop a first-in-class, anti-viral treatment for influenza by activating the body’s innate immune system specifically in locations where the virus enters the body. Our program is a differentiated approach that can also treat other seasonal and potentially newly emerging respiratory viruses. Similar to the Covid-19 program, the optimized formulation of the SNIM®RNA-carrier complex will be administered directly to the lung via inhalation to facilitate anti-viral response at the site of infection.

PAP – Pulmonary Alveolar Proteinosis
Pulmonary alveolar proteinosisis (PAP) is a rare autoimmune disease that results in difficulties in breathing due to reduced gas exchange in the lung. The underlying cause of disease in the majority of patients is the formation of auto-antibodies, which results in dysfunction of local macrophages and subsequently causes the lung’s tiny air sacs, called alveoli, to fill up with an oily substance called surfactant. There is currently no approved curative pharmacotherapy available. Our SNIM® RNA-carrier complex can be delivered directly to the lung to restore local macrophage function.

mRNA-based protein replacement therapies

PCD – Primary Ciliary Dyskinesia
Primary Ciliary Dyskinesia (PCD) is a rare disease that stems from structural defects or the absence of the cilia lining our respiratory tract. With the cilia unable to function, mucus loaded with trapped microbes, dust, and other debris cannot be cleared from the airways efficiently and can often lead to permanent lung damage. With our SNIM®RNA technology we can deliver a corrected mRNA that can produce ciliary proteins in the respiratory tract.

Delivery of corrected mRNA to maturing epithelial cells in the airways via our SNIM® RNA technology, leading to growth of normal functional cilia.